Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TOP2A | P11388 | 1/20 | 0.31 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14413824 | 0.73 | SMN1; SMN2 (0.46) | SMN1; SMN2TOP2ATOP2BALDH1A1MAPT | |
| SCHEMBL22135875 | 0.70 | SMN1; SMN2 (0.43) | SMN1; SMN2TOP2ATOP2BALDH1A1MAPT | |
| SCHEMBL11787452 | 0.68 | SMN1; SMN2 (0.47) | SMN1; SMN2TOP2ATOP2BALDH1A1MAPT | |
| SCHEMBL24399158 | 0.67 | SMN1; SMN2 (0.41) | SMN1; SMN2 | |
| SCHEMBL7438734 | 0.67 | SMN1; SMN2 (0.41) | SMN1; SMN2 | |
| SCHEMBL11788478 | 0.67 | SMN1; SMN2 (0.50) | SMN1; SMN2 | |
| SCHEMBL16885243 | 0.67 | SMN1; SMN2 (0.45) | SMN1; SMN2 | |
| SCHEMBL3743719 | 0.64 | — | — | |
| SCHEMBL248285 | 0.64 | — | — | |
| SCHEMBL4289914 | 0.63 | SMN1; SMN2 (0.50) | SMN1; SMN2OPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11014964-B2 | Peptide amide compound and preparation method and medical use thereof | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2021-05-25 | — | — | US | disclosed |
| US-20200172573-A1 | PEPTIDE AMIDE COMPOUND AND PREPARATION METHOD AND MEDICAL USE THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172573-A1 | PEPTIDE AMIDE COMPOUND AND PREPARATION METHOD AND MEDICAL USE THEREOF | VIP, NPPA, GRPR | SMN1; SMN2 2646/4885TOP2A 4632/4885TOP2B 4760/4885 |
| US-11014964-B2 | Peptide amide compound and preparation method and medical use thereof | VIP, NPPA, GRPR | SMN1; SMN2 2646/4885TOP2A 4632/4885TOP2B 4760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.